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dercutaneous Aortic
alve Replacement
ith the CoreValve Prosthesis
e read with interest the recent article of Grube et al. (1) dealing
ith percutaneous aortic valve implantation. They reported the
xperience from 3 centers using the second and third generations
f the CoreValve prosthesis (CoreValve Inc., Irvine, California) in
6 consecutive patients. The acute device success was high (88%),
nd the 30-day mortality was low (12%) in these surgically
igh-risk patients with mean pre-procedural logistic Euroscores of
1.7%. Hemodynamically, the mean transvalvular gradient
ropped from 43.7 to 9.0 mm Hg with a concomitant improve-
ent in the New York Heart Association functional class.
We would like to comment on these results and also ask for
ome clarifications regarding their data.
When reporting data after aortic valve implantation, one would
xpect to have information regarding the aortic prosthetic valve
rea and the rate of prosthesis–patient mismatch. One cannot be
atisfied by the transvalvular gradient alone, knowing that a high
roportion of patients with left ventricular systolic dysfunction
ere included in the study. These data are important because they
ill allow comparison among percutaneous valves themselves and
ith the surgically implanted prosthetic valves, thus improving the
nformation given to patients.
In the same way, we regret that the post-procedural incidence
nd severity of perivalvular leakage were not detailed as was the
ase for the pre-procedural intravalvular regurgitation.
We were surprised that exclusion criteria did not include bicuspid
ortic valves. In our experience, stent deployment may be impaired in
icuspid aortic stenosis (2), a condition with an incidence that can
each 50% of the surgically operated patients (3). Furthermore, in the
eries of Cribier et al. (4), all of the native aortic valves were tricuspid.
We were also surprised by the high rate of procedural valve
ilations after valve implantations (28% of the 76 valve implanta-
ions) to achieve good stent expansions. We wonder if this high
ate of subsequent dilation reflects undiagnosed bicuspid aortic
tenosis.
Information regarding major bleeding is lacking (a rate of 24%
as been reported in a previous study [5]). Likewise, the peripheral
ascular complications and their management were not reported.
ne would like to know whether their incidence was dependent on
he type (open [with a cut down] or closed) of vascular access
uring the procedure.
Atrioventricular block is a classic complication after surgical
ortic valve replacement. It seems that it is also the case after
ercutaneous valve implantation. Data regarding this complication
n the series should also be provided.
Finally, there is actually only one available size of CoreValve,
ith a 21-mm bioprosthesis implanted within the stent frame (2).
s researchers, we do not understand how proper sizing could be Tchieved in patients with aortic annulus diameters ranging from 20
o 27 mm. Mismatch will inevitably lead to leaflet distortion or
estriction (Rachid Zegdi, personal communication, December
006), with a potential negative impact in the long term.
Although many points of the study require further clarification,
e would like to thank the authors for their important work and
ontribution to this important new field of interventional therapy.
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eply
e would like to thank Dr. Zegdi and colleagues for their interest in
ur article (1) and would like to address the raised questions as
ollows: 1) the valve area increased from 0.60  0.16 cm2 to 1.67 
.41 cm2 post-CoreValve implantation, as suggested by the marked
ecrease of the mean transvalvular gradient. A direct comparison of
he valve areas after standard surgery versus percutaneous replacement
arries a caveat. Prosthetic valves are surgically implanted and function
ither intra-annularly or supra-annularly, whereas the CoreValve is
esigned to be placed intra-annularly but function supra-annularly.
herefore, whereas the frame anchors and adapts to the annulus
